Shenyang Neusoft Zhirui Radiotherapy Technology
Precision oncology equipment for intelligent radiotherapy treatment
About Shenyang Neusoft Zhirui Radiotherapy Technology
Shenyang Neusoft Zhirui Radiotherapy Technology, also known as IntelliRay, develops and researches oncology treatment equipment. The company was founded in 2018 and is headquartered in Shenyang, China. IntelliRay is a subsidiary of Neusoft Medical Systems, which in turn is a subsidiary of Neusoft Corporation, China's largest IT solutions and services provider. The parent company, Neusoft, was founded in 1991 by professors from Northeastern University and was the first listed software company in China.
The company focuses on creating accurate and intelligent radiotherapy technologies to improve the effectiveness of cancer treatments. Its product line includes the NeuRT Aurora, a device that provides diagnostic-grade image-guided precise irradiation, and NeuOIS, a cloud-based remote radiation therapy platform. IntelliRay's solutions are part of a broader portfolio from Neusoft Medical that includes CT scanners, MRI systems, linear accelerators, and treatment planning software. The technology incorporates features like the Collapsed Cone Convolution Superposition (CCCS) algorithm, considered a highly accurate 3D dose calculation model, and powerful 3D visualization tools.
IntelliRay operates as a venture capital-backed, privately held company. It has successfully raised capital through multiple funding rounds, including a Series C round in June 2024 that raised CNY 100 million, led by Neusoft and Lucky Capital. Other notable investors include In Capital, Lenovo Capital and Incubator Group, 6 Dimensions Capital, and Ivy Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 12.0/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jun 2024 | $14M | $55M | Neusoft · Lucky Capital | ↗ |
Growth signals
Latest recorded traffic for Shenyang Neusoft Zhirui Radiotherapy Technology is 110 monthly website visits, down 73.8% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shenyang Neusoft Zhirui Radiotherapy Technology in its local ecosystem
The Shenyang Neusoft Zhirui Radiotherapy Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Neusoft- LCLucky Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shenyang Neusoft Zhirui Radiotherapy Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shenyang Neusoft Zhirui Radiotherapy Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.